Apolipoprotein E genotype and cholesterogenesis in polygenic hypercholesterolemia

Abstract

We studied 22 normal-weight patients with polygenic hypercholesterolemia (PH), of which 11 (two males and nine females) had the apolipoprotein (apo) E3/4 genotype and 11 (one male and 10 females) the E3/3 genotype. The two groups were comparable for age, body mass index, total and low-density lipoprotein (LDL) cholesterol levels. The diagnosis of PH was made on the basis of clinical assessment, the criteria being type IIa hypercholesterolemia without tendon xanthomas and/or family history and clinical criteria indicative of familial hypercholesterolemia and/or familial combined hyperlipidemia. To avoid the influence of the habitual individual diet on cholesterogenesis, daily urinary mevalonic acid (MVA) excretion, an index of whole-body cholesterol synthesis, was evaluated in the steady-state condition while patients were on a low-fat, low-cholesterol diet for at least 3 months. Urinary MVA excretion rates were 2.52 ± 0.8 μmol/24 h in E3/4 patients, significantly higher ( P < .001) than in E3/3 patients (1.38 ± 0.6 μmol/24 h). This is the first evidence of a higher rate of cholesterogenesis in PH patients carrying the ϵ4 allele versus the ϵ3 allele under a standarized lipid-lowering diet. We conclude that the higher rate of cholesterogenesis in PH patients with the ϵ4 allele might partly explain the interindividual differences in response to treatment with cholesterol synthesis inhibitors such as statins.